Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 30;41(5):111528. doi: 10.1016/j.celrep.2022.111528

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Neutralizing activity of 18 monoclonal antibodies derived from convalescent COVID-19 patients and seven clinically approved monoclonal antibodies against different SARS-CoV-2 variants

(A) Heatmap of pseudovirus neutralization activity of 18 mAbs derived from convalescent COVID-19 patients. IC₅₀ values (μg/mL) are shown for neutralization of SARS-CoV-2 pseudoviruses bearing spike proteins from the USA/WA1/2020 isolate (WA-1, lineage A), the Alpha variant, Beta variant, Delta variant, and Omicron BA.1, BA.2, BA.4, and BA.2.12.1 sublineages. The color-coded legend of IC₅₀ ranges is indicated in (C).

(B) Neutralizing activity of seven clinically approved mAbs, including REGN-10933, REGN-10987, LY-CoV555, LY-CoV016, COV2-2130, COV2-2196, and S309 (sotrovimab), against the same SARS-CoV-2 variants as in (A).

(C) Neutralizing activity of mAbs NA8 and NE12 and six clinically approved mAbs used in paired combinations against the SARS-CoV-2 WA-1 strain and the Omicron BA.1, BA.2, BA.4, and BA.2.12.1 sublineages.

(D) Neutralization curves of mAbs NE12 and NA8 and six clinically approved mAbs used in paired combinations against the Omicron BA.1 sublineage.

(E) Neutralization curves of mAbs NE12 and NA8 and six clinically approved mAbs used in paired combinations against the Omicron BA.2 sublineage.

(F) Neutralization curves of mAbs NE12 and NA8 and six clinically approved mAbs used in paired combinations against the Omicron BA.4 sublineage.

(G) Neutralization curves of mAbs NE12 and NA8 and six clinically approved mAbs used in paired combinations against the Omicron BA.2.12.1 sublineage.

(H) Neutralization curves of mAbs NE12 and NA8 used in combination against all major SARS-CoV-2 variants of concern.

(I) Neutralization curves of mAb NA8 against the major SARS-CoV-2 variants of concern.

(J) Neutralization curves of mAb NE12 against the major SARS-CoV-2 variants of concern. Results are the average of two or three independent experiments performed in duplicate using a pseudovirus assay. Values represent mean ± SD. The dotted horizontal lines indicate the IC₉₀ and IC₅₀.

HHS Vulnerability Disclosure